Latest Information Update: 02 Aug 2001
At a glance
- Originator Sankyo
- Mechanism of Action Monoamine oxidase A inhibitors; Monoamine oxidase B inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Parkinson's disease
Most Recent Events
- 02 Aug 2001 Discontinued-Preclinical for Parkinson's disease in Japan (Unknown route)
- 01 May 2001 New profile
- 01 May 2001 Preclinical development for Parkinson's disease in Japan (Unknown route)